Last 34 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 51.77 | — | 36.86 | — | — | — | — | — | — | — | — | 8590.93 | — | 6039.17 | 8290.64 | 5951.22 | 4822.86 | 7916.07 | 4751.71 | 5277.68 | 10178.80 |
| — | — | — | — | — | — | — | — | — | — | — | +44.4% | — | -23.7% | +74.5% | +12.8% | -52.6% | -55.9% | -76.2% | +17250.8% | — | |
| P/B Ratio | 0.52 | 1.41 | 1.57 | 2.10 | 1.03 | 0.87 | 0.72 | 0.82 | 1.06 | 1.26 | 0.86 | 1.64 | 1.05 | 0.91 | 1.17 | 1.21 | 1.36 | 2.10 | 2.04 | 1.51 | 2.24 |
| — | +61.6% | +118.5% | +157.7% | -2.7% | -30.9% | -16.5% | -50.2% | +0.7% | +38.6% | -26.6% | +35.9% | -22.4% | -56.5% | -42.5% | -19.9% | -39.4% | -42.2% | -40.7% | -65.5% | -26.1% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | — | — | — | — | — | — | — | — | -16059.1% | 100.0% | -16136.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | — | — | — | — | — | — | — | — | — | — | -16159.1% | 0.0% | -16236.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | |
| Operating Margin | — | — | -1011.2% | — | — | — | — | — | — | — | — | -315927.3% | 193577.3% | -286345.5% | -366090.9% | -330306.7% | -205051.1% | -168344.9% | -89062.8% | -131134.4% | -144888.2% |
| — | — | — | — | — | — | — | — | — | — | — | +4.4% | +194.4% | -70.1% | -311.0% | -151.9% | -41.5% | -6.2% | +44.8% | -151351.7% | — | |
| Net Margin | — | — | -919.8% | — | — | — | — | — | — | — | — | -295454.5% | 202856.8% | -283122.7% | -360145.5% | -333226.7% | -201802.1% | -169689.8% | -86961.6% | -130901.6% | -146800.0% |
| — | — | — | — | — | — | — | — | — | — | — | +11.3% | +200.5% | -66.8% | -314.1% | -154.6% | -37.5% | -6.3% | +46.1% | -151934.6% | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -53.4% | -12.2% | -11.9% | -14.9% | -12.8% | -12.5% | -14.0% | -14.8% | -13.5% | -13.5% | -13.6% | -13.4% | -16.3% | -10.3% | -13.0% | -15.9% | -13.5% | -10.8% | -9.0% | -9.0% | -7.9% |
| — | +3.1% | +14.5% | -0.8% | +5.6% | +7.4% | -2.7% | -10.8% | +17.0% | -31.1% | -4.2% | +15.9% | -20.9% | +4.2% | -44.5% | -77.0% | -70.7% | -37.5% | -33.2% | -192.0% | -26.7% | |
| ROA | -39.6% | -9.5% | -9.0% | -10.5% | -9.1% | -9.1% | -10.4% | -11.3% | -10.5% | -10.7% | -10.8% | -10.6% | -13.2% | -8.4% | -10.4% | -12.7% | -11.1% | -9.1% | -7.8% | -7.9% | -7.0% |
| — | -4.4% | +13.3% | +7.2% | +13.9% | +15.2% | +3.3% | -6.9% | +20.0% | -27.7% | -3.1% | +17.0% | -18.7% | +7.3% | -33.5% | -60.9% | -57.9% | -27.8% | -27.1% | -188.8% | -25.6% | |
| ROIC | -40.7% | -9.1% | -8.8% | -10.6% | -9.3% | -9.2% | -10.7% | -11.3% | -9.7% | -11.5% | -11.3% | -10.1% | -11.3% | -8.1% | -10.6% | -11.5% | -9.8% | -7.9% | -7.0% | -7.2% | -6.7% |
| — | +0.4% | +17.6% | +6.8% | +4.5% | +20.2% | +5.6% | -12.1% | +13.8% | -42.4% | -7.2% | +12.3% | -14.4% | -2.2% | -51.4% | -60.1% | -47.0% | -14.0% | -13.9% | -165.5% | -26.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.28 | 0.17 | 0.16 | 0.29 | 0.28 | 0.27 | 0.23 | 0.21 | 0.21 | 0.18 | 0.18 | 0.21 | 0.19 | 0.17 | 0.15 | 0.17 | 0.15 | 0.13 | 0.12 | 0.08 | 0.08 |
| — | -35.8% | -29.9% | +37.8% | +32.4% | +47.1% | +25.7% | +1.5% | +15.8% | +10.7% | +24.1% | +23.4% | +22.5% | +26.9% | +20.3% | +108.5% | +91.8% | +150.3% | +144.9% | +67.3% | +58.7% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.93 | 7.79 | 10.72 | 9.65 | 7.93 | 8.19 | 8.92 | 9.71 | 8.54 | 9.35 | 12.25 | 12.80 | 12.38 | 12.58 | 9.18 | 8.08 | 9.84 | 11.64 | 11.42 | 12.74 | 9.84 |
| — | -4.9% | +20.1% | -0.7% | -7.2% | -12.4% | -27.2% | -24.1% | -31.0% | -25.7% | +33.5% | +58.4% | +25.8% | +8.0% | -19.7% | -36.6% | +0.0% | +23.9% | -12.7% | -2.4% | +9.8% | |
| Quick Ratio | 7.93 | 7.79 | 10.72 | 9.65 | 7.93 | 8.19 | 8.92 | 9.71 | 8.54 | 9.35 | 12.25 | 12.80 | 12.38 | 12.62 | 9.18 | 8.08 | 9.84 | 11.64 | 11.42 | 12.74 | 9.84 |
| — | -4.9% | +20.1% | -0.7% | -7.2% | -12.4% | -27.2% | -24.1% | -31.0% | -26.0% | +33.5% | +58.4% | +25.8% | +8.4% | -19.7% | -36.6% | +0.0% | +23.9% | -12.7% | -2.4% | +9.8% | |
| Interest Coverage | -176.57 | -131.90 | -123.42 | -141.02 | -122.99 | -119.35 | -189.09 | -397.22 | -733.52 | -661.93 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 34 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ALLO stock.
Allogene Therapeutics, Inc.'s current P/E is -1.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Allogene Therapeutics, Inc.'s business trajectory between earnings reports.